



Citi Pharma Limited

CITI PHARMA LIMITED
EXTRACT OF RESOLUTION VIA CIRCULATION
DATED: APRIL 15, 2025
(Under Section 179 of the Companies Act, 2017)

It is hereby certified that the following resolution has been circulated to all Directors of Citi Pharma Limited in accordance with Section 179 of the Companies Act, 2017. The resolution has been approved by the requisite majority of the directors and is deemed to have been passed on April 14, 2025. The same has been duly recorded in the Minutes Book of the Company.

RESOLUTION

"RESOLVED THAT the Board of Directors of Citi Pharma Limited hereby accords its approval for the Company to submit a Non-Binding Offer for the potential acquisition of leading pharmaceuticals company in Pakistan, solely for the purpose of participating in the due diligence process, subject to applicable laws, rules and regulatory requirements.

FURTHER RESOLVED THAT this approval shall not be construed as authorization to submit a binding offer or to enter into any transaction for acquisition unless specifically approved by the Board of Directors at a later stage.

FURTHER RESOLVED THAT the Chief Executive Officer, Chief Financial Officer, or any other officer duly authorized by the Company, be and are hereby empowered to negotiate, finalize, execute and submit all necessary documents and communications in relation to the non-binding offer and due diligence process, for and on behalf of the Company."

Certified to be a true copy.

Ghulam Dastgeer
Company Secretary

